COO
Cooper Companies (The)
$65.42
▼ 0.7%Updated Today 7:15 PM ET
▼ Down 5.6% over the last 12 months
Market Cap
$12.85B
P/E
54.89x
Forward P/E (est.)
78.42x
ROE
2.8%
Revenue Growth
6.1%
EPS Growth
-42.6%
Profit Margin
5.6%
FCF Yield
19.1%
Debt / Equity
0.3x
ROIC
5.0%
Interest Coverage
6.49x
Current Ratio
1.27x
Dividend Yield
0.0%
Implied Growth (rev. DCF)
5.4%
Rating Score
37/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what COO's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. COO trades near $65.42, around its 50-day average ($64.41) and 200-day average ($72.66). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 62 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. COO's is $2.03 (~3.1% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month COO found buyers near $59.14 (support) and sellers near $69.00 (resistance); its 52-week range is $58.89–$89.83. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.1× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Cooper Companies (The) (COO) is a large-cap company in the Health Care Supplies industry, part of the Health Care sector of the S&P 500, with a market value around $12.85B.
In its latest reported year it generated about $4.09B in revenue and $374.90M in net profit.
Our model rates COO Weak (37/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
8.8%
Revenue moved from $2.92B in 2021 to $4.09B in 2025, a 8.8% compound annual growth rate. The most recent year grew a steady 6.1% year over year. Slower, mature growth is common for established businesses.
Gross Margin
65.5%
Operating Margin
16.7%
Net Margin
9.2%
ROE
2.8%
Cooper Companies (The) keeps about 5.6% of each sales dollar as net profit, with a 65.5% gross margin and 16.7% operating margin. Return on equity is 2.8% and return on invested capital about 5.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$2.26B
Net Debt
$2.12B
Net Debt / EBITDA
3.11x
Debt / Equity
0.3x
Leverage: debt-to-equity is 0.3x, and operating profit covers interest about 6.5x, with a current ratio of 1.3x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $2.26B of total debt against $138.80M of cash.
Operating CF
$796.10M
Free Cash Flow
$433.70M
FCF Margin
10.6%
In the latest year Cooper Companies (The) produced about $796.10M of operating cash flow and $433.70M of free cash flow after capital spending. That is a free-cash-flow yield of about 19.1% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
54.89x
P/S
3.23x
P/B
1.65x
EV / EBITDA
14.01x
COO trades at 54.9x trailing earnings (about 78.4x on estimated forward earnings), 3.2x sales, and 1.7x book value. Reverse-engineering today's price implies the market expects roughly 5.4% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How COO stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), COO ranks #51 of 59 by our overall rating. It trades at a premium versus the sector on earnings (54.9x P/E vs. 25.4x median) with a lower return on equity (2.8% vs. 14.9%) and slower revenue growth (6.1% vs. 7.9%).
P/E vs sector
54.9x
median 25.4x
ROE vs sector
2.8%
median 14.9%
Growth vs sector
6.1%
median 7.9%
Sector rank
#51
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$83.40 – $139.00
vs. $65.42 today · expected CAGR 5% – 16%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $4.34B | $4.60B | $4.87B | $5.17B | $5.48B |
| Net income | $390.41M | $413.84M | $438.67M | $464.99M | $492.89M |
| EPS | $2.00 | $2.12 | $2.25 | $2.38 | $2.53 |
| Share price (low) | $66.06 | $70.02 | $74.22 | $78.68 | $83.40 |
| Share price (high) | $110.10 | $116.71 | $123.71 | $131.13 | $139.00 |
| CAGR (low–high) | 1% / 68% | 3% / 34% | 4% / 24% | 5% / 19% | 5% / 16% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for COO:
- Healthy free-cash-flow yield (~19.1%) funds buybacks and dividends.
- A conservative balance sheet (debt/equity 0.3x) lowers risk.
The case against COO:
- A rich 54.9x earnings multiple prices in a lot of growth.
- Our model's overall read is Weak (37/100).
Valuation risk — at 54.9x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Cooper Companies (The) is a large-cap health care business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at 54.9x earnings, which our model scores Weak (37/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.